MS Speaks

Multiple Sclerosis => TREATMENTS => MAYZENT (siponimod) => Topic started by: agate on September 17, 2019, 07:45:31 am

Title: (ECTRIMS) Siponimod delays time to wheelchair in SPMS...
Post by: agate on September 17, 2019, 07:45:31 am
Presented at ECTRIMS annual conference (September 2019) in Stockholm--"Siponimod delays time to wheelchair in SPMS: Results from the EXPAND study":


http://bit.ly/2kOaBm7


Perhaps it's an oversight but the authors don't specify "active SPMS" though other information coming about about siponimod has made it clear that only patients with SPMS that is still relapsing would benefit from this drug.


The speaker in the video (see link) may discuss this in the Q&A session after his presentation but his speech isn't clear to me.
Title: (ECTRIMS) This study called into question by ECTRIMS President
Post by: agate on October 02, 2019, 06:23:25 am
From Medscape (October 2, 2019) a short article with a somewhat misleading title--"Siponimod May Delay Wheelchair Use in SPMS." The article quotes Bernhard Hemmer, MD, the President of ECTRIMS (the conference where these findings were presented),  who raises questions about this study's claim that siponimod can delay the time to wheelchair use in SPMS.
[/size]
https://www.medscape.com/viewarticle/919261